AI & ChatGPT searches , social queries for DENOSUMAB
Search references for DENOSUMAB. Phrases containing DENOSUMAB
See searches and references containing DENOSUMAB!
Search references for DENOSUMAB. Phrases containing DENOSUMAB
See searches and references containing DENOSUMAB!DENOSUMAB
Human monoclonal antibody
Denosumab, sold under the brand names Prolia and Xgeva among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced
Denosumab
Mammalian protein found in Homo sapiens
some were given either 120 mg of denosumab or 4 mg of zoledronic acid. Patients who were given 120 mg of denosumab (in comparison to those who were given
RANKL
American multinational biopharmaceutical company
Molecular Genetics. The company's major products are Prolia and XGEVA (denosumab) to treat osteoporosis and bone diseases ($6.6 billion in total 2025 revenues)
Amgen
denopamine (INN) denosumab (USAN, INN) denosumab-bbdz denosumab-bmwo denosumab-bnht denosumab-desu denosumab-dssb denosumab-mobz denosumab-qbde denotivir
List_of_drugs:_De
American actress (born 1943)
disparities exist. She has also appeared in commercials for Prolia, a brand of denosumab used in the treatment of osteoporosis. Danner was married to producer
Blythe_Danner
Medical condition
incident occurring in 2003. Osteonecrotic complications associated with denosumab, another antiresorptive drug from a different drug category, were soon
Medication-related osteonecrosis of the jaw
Medication-related_osteonecrosis_of_the_jaw
Pharmacological term
too rapidly. Denosumab inhibits osteoclast recycling, which results in the accumulation of pre-osteoclasts and osteomorphs. When denosumab therapy is discontinued
Rebound_effect
Low calcium levels in one's blood serum
rhabdomyolysis, tumor lysis syndrome, and medications such as bisphosphonates or denosumab. Diagnosis should generally be confirmed by determining the corrected
Hypocalcemia
High calcium (Ca2+) level in the blood serum
60-90% of patients who were treated for hypercalcaemia of malignancy. Denosumab is a bone anti-resorptive agent that can be used to treat hypercalcaemia
Hypercalcaemia
Swiss pharmaceuticals and biosimilars company
relating to the US Food and Drug Administration (FDA)-approved Sandoz denosumab biosimilars. In November 2024, Sandoz inaugurated the new headquarters
Sandoz
Monoclonal antibody against amyloid beta
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Donanemab
Antibodies from clones of the same blood cell
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Monoclonal_antibody
Mosaic genetic disorder affecting the bone, skin and endocrine systems
it is no longer believed that they prevent progression of the disease. Denosumab has been found successful in reducing bone pain and decreasing tumor growth
McCune–Albright_syndrome
Pharmaceutical drug
one year, and the benefit was maintained after a second year of taking denosumab. In the other, one year of romosozumab followed by one year of alendronate
Romosozumab
Anti-tau monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Semorinemab
Variant of a biopharmaceutical
2025 denosumab-nxxp/Bildyos denosumab/Prolia August 2025 denosumab-nxxp/Bilprevda denosumab/Xgeva September 2025 denosumab-kyqq/Aukelso denosumab/Xgeva
Biosimilar
Drug class
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Anti-amyloid_antibodies
Softened section of a bone
tested in conjunction with calcium and vitamin D to encourage bone health. Denosumab, a monoclonal antibody treatment RANKl inhibitor that targets the osteocyte
Osteolytic_lesion
Male reproductive organ cancer
they shrink tumors. Other bone-modifying agents like zoledronic acid and denosumab can reduce prostate cancer bone pain, even though they have little effect
Prostate_cancer
Medical condition
and bone-targeting chemotherapeutic agents such as bisphosphonates and denosumab. Orthopedic interventions such as internal fixation or spinal decompression
Bone_metastasis
Pharmaceutical drug
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Evolocumab
Type of autoimmune arthritis
PMID 25729036. S2CID 43537545. Chiu YG, Ritchlin CT (January 2017). "Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis". Expert Opinion
Rheumatoid_arthritis
Skeletal disorder
risk of breast cancer, it increases the risk of blood clots and strokes. Denosumab is effective at preventing fractures (in general, but also specifically
Osteoporosis
Experimental monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Prasinezumab
Degeneration of a weight-bearing joint due to loss of sensation
bisphosphonates, calcitonin, parathyroid hormone, methylprednisolone, or denosumab is of no benefit and, therefore, is not recommended by the recent IWGDF
Neuropathic_arthropathy
Japanese pharmaceutical company
(esomeprazole) (only in Japan; marketed by AstraZeneca elsewhere) Pralia (denosumab) (only available in Japan; also sold there as Ranmark) Tarlige (mirogabalin)
Daiichi_Sankyo
Cancer that originates in mammary glands
metastases benefit from regular infusion of the bone-strengthening agents denosumab and the bisphosphonates; infusion every three months reduces the chance
Breast_cancer
Monoclonal antibody against amyloid beta
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Lecanemab
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Trevogrumab
American multinational pharmaceutical company
PMID 24063695. S2CID 20163452. Gauthier K, Bai A, Perras C, et al. (2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis:
Merck_&_Co.
Medical diagnostic
(2017-06-01). "FRI0568 Echosound approach for short-term follow-up of the denosumab effect on bmd recovery against aromatase inhibitor impact in breast cancer
Radiofrequency Echographic Multi Spectrometry
Radiofrequency_Echographic_Multi_Spectrometry
Medical condition
Optimal treatment for this condition is unclear. Bisphosphonates and denosumab may be of use for the bone lesions. Cyclosporine A may be of use for treating
Multicentric carpotarsal osteolysis syndrome
Multicentric_carpotarsal_osteolysis_syndrome
Veterinary medication
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Relfovetmab
Cell line
"Development of cell lines producing recombinant therapeutic proteins, with denosumab as a case study". Biological Products. Prevention, Diagnosis, Treatment
Chinese_hamster_ovary_cell
Surname list
is a brand name of a biosimilar for the monoclonal antibody medication denosumab. This page lists people with the surname Junod. If an internal link intending
Junod
Antibodies from non-human species made nearly identical to human ones
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Humanized_antibody
Medication
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Bevacizumab
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Emicizumab
Veterinary medication
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Izenivetmab
Family of transcription factor protein complexes
avenue of development for strategies targeting NF-κB inhibition. The drug denosumab acts to raise bone mineral density and reduce fracture rates in many patient
NF-κB
Chemical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Bimagrumab
Pharmaceutical biological monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Fremanezumab
Immune system messenger protein which induces inflammation
Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab
Tumor_necrosis_factor
Protein found in humans
Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab
Lymphotoxin_alpha
Drugs that inhibit α-synuclein
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Anti-α-synuclein_drug
Chemical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Erenumab
Pharmaceutical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Abciximab
Pharmaceutical drugs for preventing bone loss
C; Cunningham, J; Ahuja, T; Richter, T; Kovacs, C (February 2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis:
Bisphosphonate
Medication
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Marstacimab
Chemical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Bococizumab
Pharmaceutical drug
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Alirocumab
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Bedinvetmab
Monoclonal antibody against amyloid beta
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Aducanumab
Medication
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Idarucizumab
Pharmaceutical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Indium_(111In)_imciromab
Medication
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Concizumab
Chemical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Bapineuzumab
Chemical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Blosozumab
Experiment TNFα inhibitor
Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab
Pegipanermin
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Eptinezumab
humanized DLL4 cancer Denintuzumab mafodotin mab humanized CD19 cancer Denosumab Prolia mab human RANKL Y osteoporosis, bone metastases etc. Depatuxizumab
List of therapeutic monoclonal antibodies
List_of_therapeutic_monoclonal_antibodies
Excess hormone production by the parathyroid gland
osteoporosis such as estrogen replacement therapy, bisphosphonates, or denosumab and for treatment hypercalciuria to reduce the risk for kidney stones
Primary_hyperparathyroidism
Town and municipality in Puerto Rico
Amgen is also adding[when?] manufacturing capacity in Juncos to produce Denosumab. In addition to Amgen there is a Medtronic and Becton Dickinson Caribe
Juncos,_Puerto_Rico
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Rinucumab
Bone tumor composed of agglomerated osteoclast-like cells
osteoclast-like cells. More recently, humanized monoclonal antibodies such as Denosumab targeting the RANK ligand have been employed in treatment of GCTOB in
Giant-cell_tumor_of_bone
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Abelacimab
Chemical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Caplacizumab
Monoclonal antibody designed to treat X-linked hypophosphatemia
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Burosumab
Monoclonal antibody protein
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Gantenerumab
Medical condition
used for the treatment of osteoporosis or bone metastasis, most notably, denosumab. Purely osteoanabolic agents such as the PTH analogs, teriparatide and
Osteonecrosis_of_the_jaw
Mammalian protein found in Homo sapiens
OPG. For example, denosumab is a fully human monoclonal antibody that is directed against RANKL. In phase I and II trials, denosumab led to a decrease
RANK
Topics referred to by the same term
FREEDOM trial can refer to either of : the phase 3 clinical trial of Denosumab in osteoporosis, "Future REvascularization Evaluation in patients with
FREEDOM_trial
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Galcanezumab
Pharmaceutical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Indium_(111In)_biciromab
Antibody tested against Alzheimer's
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Crenezumab
Topics referred to by the same term
baby's sex para-Dimethylaminobenzaldehyde, an organic chemical compound Denosumab, a drug for treating osteoporosis This disambiguation page lists articles
DMAB
Monoclonal antibody medication
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Solanezumab
Pharmaceutical compound
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Amlenetug
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Ozanezumab
Form of amenorrhea and chronic anovulation
Amenorrhea (FHA) recommend against oral contraceptives, bisphosphonates, denosumab, testosterone, and leptin for the improvement of bone mass density in
Functional hypothalamic amenorrhea
Functional_hypothalamic_amenorrhea
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Etaracizumab
Medical procedure to reduce bone loss after tooth extraction
considerations to bone healing include the concurrent use of bisphosphonate, and denosumab, smoking, diabetes, immunocompromise, and infection. Another consideration
Socket_preservation
Form of immunotherapy
11/16/2015 intravenous fully human CD38 Multiple myeloma 761036 Link denosumab Prolia, Xgeva Amgen 6/1/2010 subcutaneous fully human RANKL Postmenopausal
Monoclonal_antibody_therapy
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Volociximab
Medication
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Bentracimab
Pharmaceutical drug classification
Ipriflavone M05BX02 Aluminium chlorohydrate M05BX03 Strontium ranelate M05BX04 Denosumab M05BX05 Burosumab M05BX06 Romosozumab M05BX07 Vosoritide M05BX08 Menatetrenone
ATC_code_M05
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Ponezumab
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Inclacumab
Medication for macular degeneration
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Faricimab
Pharmaceutical drug
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Ramucirumab
Pharmaceutical drug
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Ranibizumab
Protein superfamily
Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab
Tumor necrosis factor superfamily
Tumor_necrosis_factor_superfamily
Pure chemical substances produced by and for the chemical industry
adalimumab AbbVie (Before: Abbott) 2 Enbrel etanecept Amgen 3 Prolia denosumab Amgen 4 Rituxan rituximab Roche/Biogen Idec 5 Avastatin bevacizumab Roche
Fine_chemical
Membrane receptor protein found in humans
Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab
Tumor necrosis factor receptor 1
Tumor_necrosis_factor_receptor_1
Protein superfamily of cytokine receptors
Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab Lucatumumab Mapatumumab
TNF_receptor_superfamily
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Enoticumab
hypokalaemia, blood clots, interstitial lung disease and aseptic meningitis. Denosumab SC RANKL inhibitor. Osteoporosis, including drug- and cancer-related osteoporosis
List_of_antineoplastic_agents
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Icrucumab
Monoclonal antibody
musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab† Circulatory
Opicinumab
the immune system and controls bone regeneration. Targeted by mAb drug Denosumab to treat osteoporosis. CD255 not assigned CD256 APRIL (proliferation-inducing
List of human clusters of differentiation
List_of_human_clusters_of_differentiation
DENOSUMAB
DENOSUMAB
DENOSUMAB
DENOSUMAB
DENOSUMAB
DENOSUMAB
DENOSUMAB
DENOSUMAB
DENOSUMAB